Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by QContinuum1on Jun 17, 2024 12:44pm
94 Views
Post# 36092295

RE:RE:RE:RE:Buybacks are possible

RE:RE:RE:RE:Buybacks are possible
mdjbrown wrote: QC1, would it not be prudent then for the company to conserve cash, and wait a couple quarters to ensure their profitability projections are on point, before spending a third of the treasury on a NCIB?

No point in a buyback, if the corporation then needs to announce a private placement equal to or greater than a NCIB a few months later because they are low on cash.


I'm basing my suggestion on the only real guidance the company has provided over the last FY or so.  So of course, yes, it would be prudent to conserve cash if and only if there projections on break even are no longer realistic.  If that is true, say as much but then also say that M&A activities are also shelved.

Naturally LABS should not do a buyback if they project that they'd need to go to market shortly thereafter, but based on what they themselves have claimed, they ought to be near or at breakeven with nothing but tailwinds making the numbers even better for the foreseeable future. 

As stated, if their 'guidance' is no longer real, then they owe shareholders revised guidance along with commentary on why the previous is no longer achieveable.

I'm a huge fan of what Pidduck and Hunter have done for LABS, we're very lucky to have them and I personally don't get wound up about options or RSUs they gift themselves since, IMO, they've earned them.  But that said, now that the ship is stable and not taking on water, I want them to finally drive the business forward and the SP upward.  Nothing I've heard recently suggests that there is anything concrete in that regard and that we're still waiting for the same catalysts as we have been for years.  Heck, some of them have even materialized and the SP hasn't reacted even a little.  Where are the orders? 
<< Previous
Bullboard Posts
Next >>